Last year the EU, now the US Supreme Court:
"Justices rule human genes cannot be patented
Richard Wolf, USA TODAY 10:59 a.m. EDT June 13, 2013
WASHINGTON -- The Supreme Court ruled Thursday that human genes cannot be patented, a decision with both immediate benefits for some breast and ovarian cancer patients and long-lasting repercussions for biotechnology research.
...Justice Clarence Thomas wrote the decision for a unanimous court. "Myriad did not create anything," Thomas said. "To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention." "
Yet, they still ruled that cDNA's were patentable, because the technician creates something that would not have been created in nature. I'm not sure what the repercussions of that will be.
yup. :-) :-) While thousands of people were in the effort all over the place, I will take a bired moment to take a b ow and tell Mikey and all like him... F* Y* you punk . F*Y* WITH the horse you rode in on.
For an example of how clueless and impotent the BTX long positionis, do take a minute to choke on laughter by reading geronisup's interpretation of this ruling.
I'm gonna spend a few minutes later on for the sheer joy of it, speculating on the haircut BTX's pose of having $19mm in i/p took--50%?? 80% ??
Good news for Biotime, they are now free to use genes without worry of lawsuits. Also of note is the huge patent estate created for all the gene data associated with Biotimes cells and hystem.(Check BTX video update video #5).
In the short term there are pros and cons, Biotime is now free to work with many genes including the BRCA variations that Myriad had patented. On the other hand Biotimes cancer detection will have to find some work arounds to keep their technology patentable.
But yes you are right overall this is not a bad thing for them, especially in the cancer therapeutics where hystem will be used. All i can say is Dr. West was a very smart man to acquire Hystem hydrogels as well as Cell Targeting Inc.